Dana Hilt
Chief Tech/Sci/R&D Officer chez ACTINOGEN MEDICAL LIMITED
Profil
Dana Charles Hilt currently works at Actinogen Medical Ltd., as Chief Medical Officer from 2023.
Dr. Hilt also formerly worked at Amgen, Inc., as Director-Clinical Neurosciences, Guilford Pharmaceuticals, Inc., as Vice President-Clinical Research, Critical Therapeutics, Inc., as Chief Medical Officer from 2006 to 2007, FORUM Pharmaceuticals, Inc., as Chief Medical Officer & SVP-Drug Development, Ascend Pharmaceuticals, Inc., as Chief Medical Officer & SVP-Clinical Research, ASCEND Therapeutics US LLC, as Chief Medical Officer & SVP-Clinical Research, Lysosomal Therapeutics, Inc., as Chief Medical Officer from 2016 to 2019, Frequency Therapeutics, Inc., as Chief Medical Officer, and Frequency Therapeutics, Inc., as Chief Medical Officer.
Dr. Hilt received his undergraduate degree from the University of Maine and doctorate degree from Tufts University School of Medicine.
Postes actifs de Dana Hilt
| Sociétés | Poste | Début |
|---|---|---|
| ACTINOGEN MEDICAL LIMITED | Chief Tech/Sci/R&D Officer | 01/02/2023 |
Anciens postes connus de Dana Hilt
| Sociétés | Poste | Fin |
|---|---|---|
Lysosomal Therapeutics, Inc.
 Lysosomal Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lysosomal Therapeutics, Inc. engages in the innovation, research, and development in the field of neurodegeneration. It focuses in lysosomal biology in developing novel small molecules for use in the treatment of neurodegenerative diseases. The company was founded by Dimitri Krainc, Joseph Mazzulli, Henri A. Termeer, Robert J. Carpenter, Peter Wirth, Edmund J. Sybertz, and Kees Cornelis Been in 2011 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01/08/2019 |
| Critical Therapeutics, Inc. | Chief Tech/Sci/R&D Officer | 25/09/2007 |
| KORRO BIO, INC. | Chief Tech/Sci/R&D Officer | - |
ASCEND Therapeutics US LLC
 ASCEND Therapeutics US LLC Pharmaceuticals: MajorHealth Technology ASCEND Therapeutics US LLC operates as a specialty pharmaceutical company which focuses on women’s health. The firm develops and markets pharmaceutical transdermal therapies. Its products include EstroGel, a non-patch transdermal estrogen therapy. The company was founded by Jay A. Bua in 2002 and is headquartered in Herndon, VA. | Chief Tech/Sci/R&D Officer | - |
| KORRO BIO, INC. | Chief Tech/Sci/R&D Officer | - |
Formation de Dana Hilt
| University of Maine | Undergraduate Degree |
| Tufts University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| ACTINOGEN MEDICAL LIMITED | Health Technology |
| Entreprise privées | 7 |
|---|---|
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
| Critical Therapeutics, Inc. | Health Technology |
FORUM Pharmaceuticals, Inc.
 FORUM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology FORUM Pharmaceuticals, Inc. was engaged in the development of therapeutics for disorders of the central nervous system (CNS). It focused on discovering and developing treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provided improvement in cognitive and overall function. The company was founded by Thorsten Melcher in 2001 and was headquartered in Waltham, MA. | Health Technology |
| Ascend Pharmaceuticals, Inc. | |
ASCEND Therapeutics US LLC
ASCEND Therapeutics US LLC Pharmaceuticals: MajorHealth Technology ASCEND Therapeutics US LLC operates as a specialty pharmaceutical company which focuses on women’s health. The firm develops and markets pharmaceutical transdermal therapies. Its products include EstroGel, a non-patch transdermal estrogen therapy. The company was founded by Jay A. Bua in 2002 and is headquartered in Herndon, VA. | Health Technology |
Lysosomal Therapeutics, Inc.
Lysosomal Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lysosomal Therapeutics, Inc. engages in the innovation, research, and development in the field of neurodegeneration. It focuses in lysosomal biology in developing novel small molecules for use in the treatment of neurodegenerative diseases. The company was founded by Dimitri Krainc, Joseph Mazzulli, Henri A. Termeer, Robert J. Carpenter, Peter Wirth, Edmund J. Sybertz, and Kees Cornelis Been in 2011 and is headquartered in Cambridge, MA. | Health Technology |
Frequency Therapeutics, Inc.
 Frequency Therapeutics, Inc. BiotechnologyHealth Technology Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the business of developing therapeutics to activate a person's innate regenerative potential to restore function. The firm is also involved in creating and commercializing therapeutics to potentially transform the lives of individuals by repairing or reversing damage done to cells, tissue, and organs. The company was founded by Robert S. Langer, David L. Lucchino, Christopher R. Loosey, and Will J. McLean on November 13, 2014 and is headquartered in Lexington, MA. | Health Technology |
